CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 18 enrolled
Drug / intervention
Depot Lupron followed by estrogen plus placebodrug
Likely dose
Depot Lupron followed by estrogen plus placebo 11.25 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00696111
NCT00696111N/ACompleted
CompareCT.gov

PCOS, Sleep Apnea and Metabolic Risk in Women

University of Chicago·interventional·Posted Jun 12, 2008·Updated Dec 31, 2024

In Brief

A clinical study evaluating Depot Lupron followed by estrogen plus placebo for Polycystic Ovary Syndrome and Obstructive Sleep Apnea. Completed, enrolled 18 participants across 1 site.

Detailed Summary

The purpose of this study is to look at the metabolic (use of energy) and hormonal features of sleep problems in women with polycystic ovary syndrome (PCOS).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPolycystic Ovary Syndrome, Obstructive Sleep Apnea
CountriesUnited States
CollaboratorsDuke University, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Timeline

N/ACompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 12, 2008
Enrollment StartDec 1, 2007
Primary CompletionJun 30, 2022
TodayJul 2, 2026
Enrollment to primary: 14.6 yearsPosted 18.1 years ago

Interventions

Depot Lupron followed by estrogen plus placebodrug

A single intramuscular dose of depot lupron (11.25 mg). Six weeks after injection, subjects will receive daily oral doses of estrogen (2mg) plus placebo for six weeks.